Optimizing the Role of Checkpoint Inhibitors in the Management of Hodgkin Lymphoma.
Sirui Ma, Michael A Spinner
https://pubmed.ncbi.nlm.nih.gov/41698326/Actively Recruiting
Led by Michael Spinner, MD · Updated on 2026-10-20
38
Participants Needed
6
Research Sites
243 weeks
Total Duration
Researchers are evaluating a combination of pembrolizumab pembro, gemcitabine, vinorelbine, and liposomal doxorubicin GVD in patients with relapsed or refractory classic Hodgkin lymphoma cHL. This phase II, multicenter, open-label study aims to determine the complete response rate using both imaging and circulating tumor DNA ctDNA to assess minimal residual disease MRD and treatment response. The study also evaluates progression-free and overall survival, adverse events, and quality of life over time, with long-term follow-up for up to 5 years. Participants receive two 21-day cycles of pembrolizumab intravenously on day 1, alongside gemcitabine, vinorelbine, and liposomal doxorubicin administered intravenously on days 1 and 8 of each cycle. Pegfilgrastim is given for supportive care during each cycle. After two cycles, response is assessed by PETCT imaging and ctDNA testing using the Foresight CLARITY LDT platform. Based on response, participants may continue with additional pembrolizumab and GVD cycles, undergo non-transplant consolidation with pembrolizumab andor involved-site radiotherapy ISRT, or switch to salvage therapy and autologous stem cell transplant ASCT. Throughout the study, participants undergo periodic imaging and blood tests to monitor disease status, including PETCT scans and advanced ctDNA assessments. Patient-reported outcomes and quality of life are measured via standardized questionnaires. Safety monitoring includes tracking adverse events and immune-related effects. Participants are followed for up to five years to evaluate long-term outcomes and treatment effects, with the primary outcome focusing on complete response rate within four cycles of therapy.
CONDITIONS
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
U
UCSF Hematopoietic Malignancies Clinical Trial Recruitment
N
Nickole Criner
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Michael Spinner, MD
Lead Sponsor
UC Hematologic Malignancies Consortium (UCHMC)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Pembrolizumab + GVD (investigational) | Salvage chemo followed by ASCT |
|---|---|---|
| What it is | A single‑group early‑phase study testing pembrolizumab plus GVD chemotherapy guided by ctDNA monitoring for adults with relapsed or refractory classic Hodgkin lymphoma | The usual current‑care approach is salvage chemotherapy followed by autologous stem cell transplant in eligible patients |
| Role in trial | This is the only treatment arm being evaluated in the trial | Not evaluated within this study; shown here as the usual standard of care for comparison |
| Primary use | Treatment of relapsed or refractory classic Hodgkin lymphoma in adults after up to one prior regimen | Salvage therapy to achieve remission before proceeding to ASCT |
| Administration or process | Pembrolizumab combined with GVD chemotherapy; ctDNA testing used to guide therapy; optional involved‑site radiotherapy and supportive care included | Typical salvage chemotherapy regimens followed by high‑dose chemotherapy and autologous stem cell transplant |
| Important risks | Safety profile not yet well established in this ctDNA‑guided combination regimen | Salvage chemotherapy and ASCT carry known risks of toxicity from high‑dose chemotherapy and transplant procedures |
| Limitations | Single‑group design lacks randomized comparison; small sample size limits generalizability | Requires patients to be eligible for and tolerate high‑dose chemotherapy and transplant, which may not apply to all relapsed patients |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 6 weeks
Participants receive two 21-day cycles of pembrolizumab plus chemotherapy drugs gemcitabine, vinorelbine, and liposomal doxorubicin. Pegfilgrastim is given for supportive care. After these cycles, response is assessed by PET/CT imaging and ctDNA testing.
Visits on days 1 and 8 of each cycle
Duration - Variable, up to several months
Participants who respond may receive up to two additional cycles of pembrolizumab plus chemotherapy or non-transplant consolidation with pembrolizumab and/or radiotherapy. Those without response may proceed to salvage therapy and autologous stem cell transplant.
Additional imaging and assessments as needed
Duration - Up to 5 years
Participants are followed for up to 5 years to monitor long-term effects, disease status, quality of life, and safety outcomes.
Periodic visits and assessments throughout follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Sirui Ma, Michael A Spinner
https://pubmed.ncbi.nlm.nih.gov/41698326/Michael Spinner, MD
Lead Sponsor
UC Hematologic Malignancies Consortium (UCHMC)
Collaborating Sponsor